Skip to main content
BioCentury Innovations (formerly SciBX)
< Next Issue 1 2 3 4 5 Prior Issue >
As published Thursday, April 23, 2015

By Lauren Martz, Staff Writer

More than four years after Nimbus Therapeutics LLC's partners at the National Cancer Institute discovered the therapeutic potential of IRAK4 inhibitors in B cell lymphoma, the company is still in preclinical development, but new competitors are closing in. At least three other biotechs have disclosed interest in the target for cancer, and two of them might beat Nimbus to the clinic.

This week, Aurigene Discovery Technologies Ltd. and TG Therapeutics Inc. presented preclinical data at the American Association for Cancer Research (AACR) meeting showing efficacy of their respective IRAK4 inhibitors in cancer cells.

Haas, M. "Nimbus' lymphoma watershed." BioCentury (2012)
Lou, K.-J. "New axis in lymphoma." SciBX: Science Business eXchange (2011)
Ngo, V., et al. "Oncogenically active MYD88 mutations in human lymphoma." Nature (2011)